Metabolic disorders among HIV-infected patients treated with protease inhibitors: A review

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue SUPPL. 1, 2000, Pages

  Graham, N M ^a  

^a VircoLab Inc   (United States)

Author keywords

Human immunodeficiency virus; Lipodystrophy; Metabolic disorders; Protease inhibitors

Indexed keywords

ALITRETINOIN; CHYLOMICRON; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RETINOIC ACID; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; CLINICAL FEATURE; CONFERENCE PAPER; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INCIDENCE; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; WASTING SYNDROME;

EID: 0034300392     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200010001-00002     Document Type: Conference Paper

References (37)

1. Protease inhibitors for HIV infection
2. Therapy for human immunodeficiency virus infection - What have we learned?
3. HIV-1 protease inhibitors: A review for clinicians
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
6. Combination antiretroviral therapy of HIV-associated microsporidiosis and cryptosporidiosis
7. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel
8. Buffalo hump in a patient with acquired immunodeficiency syndrome
9. Body composition measurements by anthropometry and bioelectrical impedance to evaluate redistribution of body fat in HIV-positive patients on antiretroviral treatment
10. Lipodystrophy associated with an HIV-protease inhibitor
11. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
12. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy: Clinical, immunological, and metabolic analyses
13. Multiple symmetrical lipomatosis associated with protease inhibitor therapy
14. Hypertrophy of the breasts in a patient treated with indinavir
15. 'Buffalo hump' in men with HIV-1 infection
16. Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA summary
17. Increased intra-abdominal fat deposits in patients on indinavir
18. 'Protease paunch' in HIV+ persons receiving protease inhibitor therapy: Incidence, risk, and endocrinologic evaluation
19. Development of a cervical fat pad following treatment with HIV-1 protease inhibitors
20. Atypical accumulation of fatty tissue
21. Cumulative risk for developing protease inhibitor-associated lipodystrophy (PI-AL) in HIV-infected patients
22. Indinavir-associated lipodystrophy
23. Adherence and effectiveness of highly active antiretroviral therapy
24. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
25. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome
26. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS
27. The non-genetics determinants of central adiposity
28. The insulin-resistance-dyslipidemic syndrome: Contribution of visceral obesity and therapeutic implications
29. Indinavir enhances retinoic acid signaling: Nelfinavir, saquinavir, and ritonavir inhibit retinoid effects in vitro
30. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
31. Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells
32. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
33. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection
34. Medical hazards of obesity
35. The fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
36. Effects of nonesterified fatty acid availability on tissue specific glucose utilisation in rats in vivo
37. Effects of lipids on blood glucose regulation and insulin action